JP2014532688A - ｐ３８を阻害するための薬物およびそれらの用途 - Google Patents

ｐ３８を阻害するための薬物およびそれらの用途 Download PDF

Info

Publication number
JP2014532688A
JP2014532688A JP2014539368A JP2014539368A JP2014532688A JP 2014532688 A JP2014532688 A JP 2014532688A JP 2014539368 A JP2014539368 A JP 2014539368A JP 2014539368 A JP2014539368 A JP 2014539368A JP 2014532688 A JP2014532688 A JP 2014532688A
Authority
JP
Japan
Prior art keywords
compound
formula
group
use according
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014539368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532688A5 (enExample
Inventor
フェデリコ、マヨール、メネンデス
クリスティーナ、ムルガ、モンテシノス
ペドロ、マヌエル、カンポス、ムエラス
ヤコバ、ヨハナ、エイジネン
アナ、マリナ、アグネス、アントニウス、カベラールス
アントニオ、モレアレ、デ、レオン
ルーベン、ヒル、レドンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Publication of JP2014532688A publication Critical patent/JP2014532688A/ja
Publication of JP2014532688A5 publication Critical patent/JP2014532688A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2014539368A 2011-11-02 2012-10-31 ｐ３８を阻害するための薬物およびそれらの用途 Pending JP2014532688A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201131754 2011-11-02
ES201131754A ES2396764B1 (es) 2011-11-02 2011-11-02 FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
PCT/ES2012/070762 WO2013064714A1 (es) 2011-11-02 2012-10-31 Fármacos inhibidores de p38 y aplicaciones

Publications (2)

Publication Number Publication Date
JP2014532688A true JP2014532688A (ja) 2014-12-08
JP2014532688A5 JP2014532688A5 (enExample) 2015-12-17

Family

ID=48191418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539368A Pending JP2014532688A (ja) 2011-11-02 2012-10-31 ｐ３８を阻害するための薬物およびそれらの用途

Country Status (9)

Country Link
US (1) US9096554B2 (enExample)
EP (1) EP2774613A4 (enExample)
JP (1) JP2014532688A (enExample)
KR (1) KR20140085580A (enExample)
AU (1) AU2012331016A1 (enExample)
BR (1) BR112014010560A2 (enExample)
CA (1) CA2854349A1 (enExample)
ES (1) ES2396764B1 (enExample)
WO (1) WO2013064714A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
EP3054955B1 (en) * 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503591A (ja) * 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
US20080039461A1 (en) 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
EP1545535A4 (en) 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
WO2005032551A1 (en) 2003-09-30 2005-04-14 Scios Inc. TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
EP1885181A2 (en) 2005-05-23 2008-02-13 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
GB0713311D0 (en) 2007-07-10 2007-08-22 Nene Group Plc Pallet racking shield
DE102007060008A1 (de) 2007-12-13 2009-06-18 Technolas Gmbh Ophthalmologische Systeme Bestimmung und Überwachumg von Laserenergie
US8637556B2 (en) 2009-01-16 2014-01-28 University of Pittsburgh—of the Commonwealth System of Higher Education Linked Myc-max small molecule inhibitors
US20120122896A1 (en) * 2009-05-08 2012-05-17 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication
ES2396764B1 (es) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503591A (ja) * 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN 1292724-70-9等（全１０６化合物）, JPN6016029508, March 2011 (2011-03-01), ISSN: 0003373300 *

Also Published As

Publication number Publication date
US9096554B2 (en) 2015-08-04
EP2774613A4 (en) 2015-04-22
WO2013064714A8 (es) 2014-06-12
ES2396764B1 (es) 2013-12-19
CA2854349A1 (en) 2013-05-10
KR20140085580A (ko) 2014-07-07
EP2774613A1 (en) 2014-09-10
AU2012331016A1 (en) 2014-06-26
ES2396764A1 (es) 2013-06-19
WO2013064714A1 (es) 2013-05-10
US20140296308A1 (en) 2014-10-02
BR112014010560A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
JP5416696B2 (ja) オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用
JP6795517B2 (ja) ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用
JP7631235B2 (ja) 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
AU2017272151B2 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
US11331286B2 (en) Inhibitors and their uses
JP2010502618A (ja) セロトニン５−ｈｔ２ａ受容体のモジュレータとしてのベンゾフラン誘導体
CA3112695C (en) Composition for treating fibrotic diseases, comprising benzhydryl thioacetamide compound as active ingredient
WO2007149782A2 (en) Selective inhibitors for transferases
KR20100015857A (ko) Ｓ1ｐ 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체
KR20160023839A (ko) 간질성 방광염/방광통증 증후군과 관련된 통증의 예방 및 치료를 위한 시그마 리셉터 리간드들의 용도
JPWO2007020888A1 (ja) 脳・神経細胞保護剤および睡眠障害治療薬
EP2951164A1 (en) Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
JP2002053566A (ja) チアゾール化合物及びその医薬用途
CN110214133A (zh) N-{[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并噁嗪-7-基)乙酰胺衍生物及相关化合物作为RORγ调节剂用于治疗自体免疫疾病
WO2004071509A1 (ja) オリゴデンドロサイト分化促進剤
JP2014532688A (ja) ｐ３８を阻害するための薬物およびそれらの用途
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
CN117529474A (zh) N-取代苯基磺酰胺类化合物及其用途
US12384751B2 (en) Allosteric activators of the ALPHA1A-adrenergic receptor
CN118541366A (zh) 二氢噁唑衍生物化合物
HUE028725T2 (en) Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170124